Anita Hill Selected Research

Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)

3/2021	One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
1/2021	Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor.
1/2021	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
1/2020	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
1/2020	Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
1/2019	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
1/2019	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry.
1/2019	Novel insights into the treatment of complement-mediated hemolytic anemias.
1/2019	Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
11/2018	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anita Hill Research Topics

Disease

28	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 03/2021 - 10/2005
22	Hemolysis 03/2022 - 10/2005
7	Thrombosis (Thrombus) 01/2020 - 01/2009
5	Aplastic Anemia (Anemia, Hypoplastic) 01/2022 - 01/2018
5	Fatigue 03/2021 - 09/2006
5	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2021 - 01/2017
4	Chronic Disease (Chronic Diseases) 03/2021 - 09/2006
2	Neoplasms (Cancer) 08/2021 - 09/2006
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019 - 01/2018
2	Cytopenia 12/2013 - 09/2007
2	Pulmonary Hypertension 05/2010 - 01/2009
1	Infections 01/2021
1	Genetic Risk Score 01/2019
1	Headache (Headaches) 01/2019
1	Anemia 01/2019
1	Lymphoma (Lymphomas) 01/2019
1	Meningococcal Infections 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Obesity 01/2015
1	Pancytopenia 12/2013
1	Splenomegaly 12/2013
1	Left Ventricular Dysfunction 08/2012
1	Hyperpigmentation 12/2010
1	Chronic Renal Insufficiency 08/2010
1	Right Ventricular Dysfunction 05/2010
1	Hypertension (High Blood Pressure) 05/2010
1	Hemolytic Anemia 04/2010
1	Congenital Abnormalities (Deformity) 01/2010
1	Hypothyroidism 11/2009
1	Thromboembolism 12/2007
1	Insulin Resistance 10/2007
1	Birth Weight (Birth Weights) 10/2007
1	Hemoglobinuria 09/2007
1	Lethargy 05/2007
1	Erectile Dysfunction 05/2007
1	Abdominal Pain (Pain, Abdominal) 05/2007
1	Deglutition Disorders (Dysphagia) 05/2007
1	CD59 Deficiency 03/2006
1	Dystonia (Limb Dystonia) 12/2005

Drug/Important Bio-Agent (IBA)

27	eculizumab FDA Link 03/2022 - 10/2005
15	Complement System Proteins (Complement)IBA 01/2020 - 10/2005
7	Complement Inactivating AgentsIBA 01/2021 - 09/2006
6	ravulizumabIBA 03/2021 - 11/2018
4	Monoclonal AntibodiesIBA 11/2018 - 09/2006
3	GPI-Linked ProteinsIBA 08/2021 - 11/2012
3	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 08/2021 - 03/2006
3	Hemoglobins (Hemoglobin)IBA 01/2019 - 01/2009
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2012 - 05/2007
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 04/2010 - 10/2005
2	eltrombopag FDA Link 01/2022 - 11/2019
2	Bendamustine Hydrochloride FDA Link 01/2020 - 11/2018
2	Rituximab (Mabthera)FDA Link 01/2020 - 11/2018
2	AntibodiesIBA 01/2020 - 03/2016
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 08/2012
2	Insulin (Novolin)FDA Link 01/2019 - 10/2007
2	C-PeptideIBA 01/2019 - 01/2018
2	pro-brain natriuretic peptide (1-76)IBA 08/2012 - 05/2010
2	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2012 - 05/2010
1	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022
1	Erythropoietin FDA Link 01/2021
1	FibrinIBA 01/2020
1	AntigensIBA 01/2019
1	AutoantibodiesIBA 01/2019
1	GlobulinsIBA 11/2018
1	CreatinineIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2017
1	Triglycerides (Triacylglycerol)IBA 01/2015
1	Glucose (Dextrose)FDA LinkGeneric 01/2015
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2015
1	VitaminsIBA 01/2015
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2015
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 11/2012
1	Proteins (Proteins, Gene)FDA Link 11/2012
1	Complement C3-C5 Convertases (C3 Convertase)IBA 11/2012
1	Membrane Proteins (Integral Membrane Proteins)IBA 11/2012
1	Warfarin (Coumadin)FDA LinkGeneric 06/2011
1	Daunorubicin (Cerubidine)FDA LinkGeneric 12/2010
1	Arginine (L-Arginine)FDA Link 05/2010
1	HaptoglobinsIBA 04/2010
1	DiamondIBA 01/2010
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 11/2009
1	ProinsulinIBA 10/2007

Therapy/Procedure

9	Therapeutics 01/2022 - 12/2005
2	Blood Transfusion (Blood Transfusions) 12/2013 - 01/2009
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2019
1	Vegetarian Diet (Vegetarianism) 01/2015
1	Splenectomy 12/2013